挪威水痘与带状疱疹相关医疗费用研究
挪威未实施水痘或带状疱疹常规疫苗接种,本研究利用2008至2014年注册数据估算两种疾病的医疗费用。总费用54%来自住院治疗的带状疱疹患者。
要点
- 带状疱疹占总费用73%,水痘占27%。
- 总费用54%为住院带状疱疹患者的费用。
核心结论
- 水痘和带状疱疹给挪威国家医疗服务带来显著经济负担。
- 大部分费用由带状疱疹造成,而带状疱疹可通过疫苗接种预防。
研究设计与样本
- 基于2008至2014年患者与初级和专科医疗服务接触的注册数据,估算水痘和带状疱疹在初级和医院护理部门的费用。
- 按治疗机构(全科医生和急诊初级保健诊所)计算初级保健个体费用,按治疗级别(住院、门诊或日间治疗)计算医院费用。
主要发现
- 年费用中73%与带状疱疹相关,27%由水痘导致。
- 总年费用的54%为医院治疗的带状疱疹患者。
临床怎么用
- 提示挪威若引入带状疱疹疫苗接种可能减轻相关医疗费用负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Norway does not implement routine vaccination against varicella or herpes zoster. Despite substantial health burden associated with both diseases, their economic impact is not well described. The aim of the present study was to document the healthcare costs associated with both conditions in a Norwegian setting. METHODS: We used registry data about patients' contacts with primary and specialized healthcare services from 2008 to 2014 to estimate the costs associated with varicella and herpes zoster in the primary and hospital care sector. We calculated the individual costs by treatment facility (general practitioner and emergency primary care clinic) in primary care and by treatment level (inpatient, outpatient or ambulatory treatment) at hospitals. RESULTS: We estimate that the annual healthcare cost of patients with varicella and herpes zoster are NOK 85 million (approximately € 9 million). Of the annual costs, 73% are associated with herpes zoster and 27% are due to varicella. The majority (54%) of the total annual cost is represented by patients with herpes zoster treated in hospital. CONCLUSION: Varicella and herpes zoster impose a substantial financial burden on the national healthcare services in Norway. Most of the costs are incurred by herpes zoster, which could be prevented by vaccination.
引用
- Haugnes H, Flem E, Wisløff T, et al. Healthcare costs associated with varicella and herpes zoster in Norway. Vaccine. 2019. PMID: 31151798. doi:10.1016/j.vaccine.2019.05.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。